Cargando…

Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study

We aimed to explore the medium- and long-term (≥12 weeks) effects of dapagliflozin on serum uric acid (SUA) level in patients with type 2 diabetes mellitus (T2DM) in the real world study and to explore the influencing factors of dapagliflozin on reducing SUA level. This observational, prospective co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shihan, Yuan, Tao, Song, Shuoning, Duo, Yanbei, Zhao, Tianyi, Gao, Junxiang, Fu, Yong, Dong, Yingyue, Zhao, Weigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861887/
https://www.ncbi.nlm.nih.gov/pubmed/36675682
http://dx.doi.org/10.3390/jpm13010021
_version_ 1784874954186031104
author Wang, Shihan
Yuan, Tao
Song, Shuoning
Duo, Yanbei
Zhao, Tianyi
Gao, Junxiang
Fu, Yong
Dong, Yingyue
Zhao, Weigang
author_facet Wang, Shihan
Yuan, Tao
Song, Shuoning
Duo, Yanbei
Zhao, Tianyi
Gao, Junxiang
Fu, Yong
Dong, Yingyue
Zhao, Weigang
author_sort Wang, Shihan
collection PubMed
description We aimed to explore the medium- and long-term (≥12 weeks) effects of dapagliflozin on serum uric acid (SUA) level in patients with type 2 diabetes mellitus (T2DM) in the real world study and to explore the influencing factors of dapagliflozin on reducing SUA level. This observational, prospective cohort study was based on the real world. There were 77 patients included in this study. They were divided into two groups. Patients in treatment group (n = 38) were treated as dapagliflozin 10 mg/d combined with therapy of routine glucose-lowering drugs (GLDs), and patients in the control group (n = 39) were treated with their routine GLDs. All measurements of physical examinations, blood, and urine samples, including age, sex, weight, height, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), and SUA, were collected at baseline for all patients in these two groups and repeated after 12, 24, and 48 weeks of therapy. We compared the changes of metabolic indicators including SUA in these two groups to evaluate the effects of dapagliflozin and analyzed its influencing factors. In the dapagliflozin group, mean SUA levels significantly decreased from 334.2 ± 99.1 μmol/L at baseline to 301.9 ± 73.2 μmol/L after 12 weeks therapy (t = 2.378, p = 0.023). There was no significant statistical difference of SUA levels after 24 weeks treatment of dapagliflozin compared with 12-week and 48-week treatment with dapagliflozin (p > 0.05). We found that baseline SUA had a significant impact on the effect of dapagliflozin on reducing SUA (OR 1.014, 95%CI 1.003–1.025, p = 0.014) by logistic regression analysis. Receiver operating characteristic (ROC) curve showed that T2DM patients with SUA level ≥ 314.5 μmol/L had relative accuracy in recognizing the good effects of dapagliflozin on reducing SUA (sensitivity 76.9%, specificity 76.2%). Combination therapy of dapagliflozin with routine blood-glucose-lowering drugs in T2DM patients showed the significant and sustained stable effect of lowering SUA level in this real-world study.
format Online
Article
Text
id pubmed-9861887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98618872023-01-22 Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study Wang, Shihan Yuan, Tao Song, Shuoning Duo, Yanbei Zhao, Tianyi Gao, Junxiang Fu, Yong Dong, Yingyue Zhao, Weigang J Pers Med Article We aimed to explore the medium- and long-term (≥12 weeks) effects of dapagliflozin on serum uric acid (SUA) level in patients with type 2 diabetes mellitus (T2DM) in the real world study and to explore the influencing factors of dapagliflozin on reducing SUA level. This observational, prospective cohort study was based on the real world. There were 77 patients included in this study. They were divided into two groups. Patients in treatment group (n = 38) were treated as dapagliflozin 10 mg/d combined with therapy of routine glucose-lowering drugs (GLDs), and patients in the control group (n = 39) were treated with their routine GLDs. All measurements of physical examinations, blood, and urine samples, including age, sex, weight, height, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), and SUA, were collected at baseline for all patients in these two groups and repeated after 12, 24, and 48 weeks of therapy. We compared the changes of metabolic indicators including SUA in these two groups to evaluate the effects of dapagliflozin and analyzed its influencing factors. In the dapagliflozin group, mean SUA levels significantly decreased from 334.2 ± 99.1 μmol/L at baseline to 301.9 ± 73.2 μmol/L after 12 weeks therapy (t = 2.378, p = 0.023). There was no significant statistical difference of SUA levels after 24 weeks treatment of dapagliflozin compared with 12-week and 48-week treatment with dapagliflozin (p > 0.05). We found that baseline SUA had a significant impact on the effect of dapagliflozin on reducing SUA (OR 1.014, 95%CI 1.003–1.025, p = 0.014) by logistic regression analysis. Receiver operating characteristic (ROC) curve showed that T2DM patients with SUA level ≥ 314.5 μmol/L had relative accuracy in recognizing the good effects of dapagliflozin on reducing SUA (sensitivity 76.9%, specificity 76.2%). Combination therapy of dapagliflozin with routine blood-glucose-lowering drugs in T2DM patients showed the significant and sustained stable effect of lowering SUA level in this real-world study. MDPI 2022-12-22 /pmc/articles/PMC9861887/ /pubmed/36675682 http://dx.doi.org/10.3390/jpm13010021 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Shihan
Yuan, Tao
Song, Shuoning
Duo, Yanbei
Zhao, Tianyi
Gao, Junxiang
Fu, Yong
Dong, Yingyue
Zhao, Weigang
Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
title Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
title_full Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
title_fullStr Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
title_full_unstemmed Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
title_short Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
title_sort medium- and long-term effects of dapagliflozin on serum uric acid level in patients with type 2 diabetes: a real-world study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861887/
https://www.ncbi.nlm.nih.gov/pubmed/36675682
http://dx.doi.org/10.3390/jpm13010021
work_keys_str_mv AT wangshihan mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT yuantao mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT songshuoning mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT duoyanbei mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT zhaotianyi mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT gaojunxiang mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT fuyong mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT dongyingyue mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy
AT zhaoweigang mediumandlongtermeffectsofdapagliflozinonserumuricacidlevelinpatientswithtype2diabetesarealworldstudy